CClinicalTrials.gg
Sign In
CompletedNCT04243083Updated Mar 30, 2021

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

A Phase 1 interventional study of TLL018 tablet, placebo in Healthy, sponsored by TLL Pharmaceutical, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-30.

Sponsored by TLL Pharmaceutical, LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 9 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

TLL018 is developed for treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. The purposes of this study are (1) determining if and at what doses TLL018 is safe and can be tolerated when administered to humans, (2) assessing what TLL018 does to the body and how the body responds to TLL018 when given as single and multiple doses, and (3) assessing potential food effect on TLL018.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

TLL Pharmaceutical, LLC is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Are capable of giving informed consent and complying with study procedures;
  2. Are between the ages of 18 and 55 years, inclusive;

  3. Female subjects have a negative serum hCG or urine pregnancy test result at screening and Day -1, and meet one of the following criteria:

    1. Using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]

    2. Surgically sterile, with documentation, for at least 3 months prior to screening by one of the following means:

      • Bilateral tubal ligation
      • Bilateral salpingectomy (with or without oophorectomy)
      • Surgical hysterectomy
      • Bilateral oophorectomy (with or without hysterectomy)

    3. Postmenopausal, defined as the following:

      • Last menstrual period greater than 12 months prior to screening
      • Postmenopausal status confirmed by serum follicle stimulating hormone (FSH) and estradiol levels at screening;
  4. Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;
  5. Normal renal function as determined by Investigator following review of clinical laboratory test results;
  6. Non-smoker or no more than 2 tobacco-containing including nicotine replacement products in last 6 months;
  7. Body mass index (BMI) of 18.0 to 30.0 kg/m2 inclusive and body weight not less than 50 kg; Subjects with BMI between 30 and 32 kg/m2 may be allowed to participate with the sponsor's approval;
  8. Willing and able to adhere to study restrictions and to be confined at the clinical research center;
  9. Male subjects with female partners of child-bearing potential must agree to use condoms for the duration of the study and until 12 weeks after dosing with the study drug and must refrain from donating sperm for this same period;
  10. Ability to swallow and retain oral medication.

Exclusion criteria

Exclusion Criteria:

  1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;
  2. Pregnant (as determined by pregnancy test result) and breastfeeding women;
  3. Current and/or recent history (\<30 days prior to screening and/or \<45 days prior to randomization) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection;
  4. Current clinically significant viral infection;
  5. Evidence of latent or active tuberculosis, as well as recent exposure or live vaccinations
  6. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin;
  7. History of pancreatitis or gall stones;
  8. History of unexplained syncope, symptomatic hypotension or hypoglycemia;
  9. Family history of long QTc syndrome; History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically significant. QTcF interval >440 msec for males and >460 msec for females;
  10. Resting pulse \<45 bpm or >100 bpm at screening, only with Day -1 as PI judgement;
  11. History of unstable ischemic heart disease or uncontrolled hypertension (blood pressure >140/90 mm Hg at screening, only with Day -1 as PI judgement);
  12. History of stomach or intestinal surgery, except that appendectomy and/or cholecystectomy will be allowed;
  13. History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance;
  14. Poor venous access;
  15. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
  16. Donated or lost >500 ml of blood in the previous 3 months;
  17. Taken any prescription medications within 7 days or 5 half-lives (whichever is longer) of the first dose of study drug;
  18. Hospital admission or major surgery within 6 months prior to screening;
  19. A history of prescription drug abuse, or illicit drug use within 9 months prior to screening;
  20. A history of alcohol abuse according to medical history within 9 months prior to screening;
  21. A positive screen for alcohol or drugs of abuse at screening or Day -1;
  22. An unwillingness or inability to comply with food and beverage restrictions during study participation;
  23. Use of over-the-counter (OTC) medication within 7 days, and herbal (including St John's Wort, herbal teas, garlic extracts) within 7 days prior to dosing (Note: Use of acetaminophen at \<2 g/day is permitted until 24 hours prior to dosing);
  24. Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational drug protocol;
  25. Hemoglobin, WBC, or platelet count below the lower reference limit of the testing laboratory. Absolute neutrophil count \<2000 cells/uL;
  26. Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose (SAD)

    There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.

    Drug: TLL018 tablet, placebo

  • Experimental
    Multiple Ascending Dose (MAD)

    There are multiple dose levels or cohorts. Each cohort has 6 subjects randomized to active drugs and 2 subjects randomized to placebo.

    Drug: TLL018 tablet, placebo

  • Experimental
    Food Effect Panel

    Twelve subjects will receive a single dose of TLL018 in 2 treatment periods, one after a high fat, high calorie breakfast (fed) and the second treatment period under fasted conditions to determine the effect of food on the PK of TLL018.

    Drug: TLL018 tablet, placebo

Interventions

  • DrugTLL018 tablet, placebo

    Oral QD

06

What researchers measure

Primary outcomes

  1. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  2. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Number of adverse events (AEs) according to severity

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  3. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Change of blood pressure from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  4. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Change of pulse rate from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  5. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Change of respiratory rate from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  6. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Change of oral temperature from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  7. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Number of participants with clinical laboratory abnormalities compared to baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  8. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  9. Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Cohorts: Number of participants with changes in physical examination findings from baseline

    Time frame: Screening up to Day 8 for SAD; Screening up to Day 14 for MAD

  10. Single Ascending Dose (SAD) Cohort: Maximum observed plasma concentration (Cmax) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  11. Single Ascending Dose (SAD) Cohort: Time to reach maximum observed plasma concentration (Tmax) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  12. Single Ascending Dose (SAD) Cohort: Plasma decay half-life (t1/2) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  13. Single Ascending Dose (SAD) Cohort: Area under the curve from time zero to last quantifiable concentration (AUClast) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  14. Single Ascending Dose (SAD) Cohort: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  15. Single Ascending Dose (SAD) Cohort: Mean residence time (MRT) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  16. Single Ascending Dose (SAD) Cohort: Apparent clearance (CL/F) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  17. Single Ascending Dose (SAD) Cohort: Apparent volume of distribution (Vz/F) of TLL018

    Time frame: 0 hour (pre-dose - within 60 minutes prior to dosing), and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  18. Multiple Ascending Dose (MAD) Cohort: Maximum observed plasma concentration (Cmax) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  19. Multiple Ascending Dose (MAD) Cohort: Time to reach maximum observed plasma concentration (Tmax) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  20. Multiple Ascending Dose (MAD) Cohort: Plasma decay half-life (t1/2) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  21. Multiple Ascending Dose (MAD) Cohort: Area under the curve from time zero to last quantifiable concentration (AUClast) of TLL018 following oral single ascending dose administration of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  22. Multiple Ascending Dose (MAD) Cohort: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  23. Multiple Ascending Dose (MAD) Cohort: Mean residence time (MRT) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  24. Multiple Ascending Dose (MAD) Cohort: Apparent clearance (CL/F) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  25. Multiple Ascending Dose (MAD) Cohort: Apparent volume of distribution (Vz/F) of TLL018

    Time frame: Day 1 (first dose) at pre-dose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post-dose; on Days 3 to 6, pre-dose; on Day 7 (last dose): pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  26. Single Ascending Dose (SAD) Cohort: Amount of TLL018 recovered unchanged in the urine over the time interval Tau (Aetau)

    Time frame: Day 1 at pre-dose up to 72 hours post-dose

  27. Single Ascending Dose (SAD) Cohort: Percentage of dose of TLL018 recovered unchanged in the urine over the time interval Tau (Aetau %)

    Time frame: Day 1 at pre-dose up to 72 hours post-dose

  28. Single Ascending Dose (SAD) Cohort: Renal clearance (CLr) of TLL018

    Time frame: Day 1 at pre-dose up to 72 hours post-dose

  29. Food Effect Cohort: Maximum observed plasma concentration (Cmax) of a single oral dose of TLL018

    Time frame: 0-hour pre-dose (within 60 minutes prior to dosing) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  30. Food Effect Cohort: Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUCinf) of a single oral dose of TLL018

    Time frame: 0-hour pre-dose (within 60 minutes prior to dosing) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  31. Food Effect Cohort: Area under the curve from time zero to last quantifiable concentration (AUClast) of a single oral dose of TLL018

    Time frame: 0-hour pre-dose (within 60 minutes prior to dosing) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  32. Food Effect Cohort: Time to reach maximum observed plasma concentration (Tmax) of a single oral dose of TLL018

    Time frame: 0-hour pre-dose (within 60 minutes prior to dosing) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

  33. Food Effect Cohort: Plasma decay half-life (t1/2) of a single oral dose of TLL018

    Time frame: 0-hour pre-dose (within 60 minutes prior to dosing) and at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours post-dose

Secondary outcomes

  1. Single Ascending Dose (SAD) Cohort: Changes of white blood cell, neutrophil and lymphocyte counts and platelets from baseline

    Time frame: 0 hour (pre-dose), 4, 8, 12, 24, 48, and 72 hours post-dose

  2. Single Ascending Dose (SAD) Cohort: Changes of high sensitivity C-reactive protein (hsCRP) and interferon gamma-induced protein 10 (IP-10) concentrations in blood from baseline

    Time frame: 0 hour (pre-dose), 4, 8, 12, 24, 48, and 72 hours post-dose

  3. Single Ascending Dose (SAD) Cohort: Effect on phospho-STAT3 levels in blood cells compared to untreated baseline

    Time frame: 0 hour (pre-dose), 1, 4, 6, 12, 24, and 48 hours post-dose

  4. Multiple Ascending Dose (MAD) Cohort: Changes of white blood cell, neutrophil and lymphocyte counts and platelets from baseline

    Time frame: Day 1 pre-dose, 4, 8, 12 hours post-dose, 24 hours pre-dose, Day 7 pre-dose, 4, 8, 12, 24, 48 and 72 hours post-dose

  5. Multiple Ascending Dose (MAD) Cohort: Changes of high sensitivity C-reactive protein (hsCRP) and interferon gamma-induced protein 10 (IP-10) concentrations in blood from baseline

    Time frame: Day 1 pre-dose, 4, 8, 12 hours post-dose, 24 hours pre-dose, Day 7 pre-dose, 4, 8, 12, 24, 48 and 72 hours post-dose

07

Study locations

1 site
  • Frontage Clinical Services, Inc.
    Secaucus, New Jersey 07094, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04243083
Lead sponsor
TLL Pharmaceutical, LLC
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Jan 26, 2020
Primary completion
Dec 23, 2020
Completion
Jan 31, 2021
Last update
Mar 30, 2021

Study contacts

Frank Lee, MD
study director · Frontage Clinical Services

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

TLL Pharmaceutical, LLC

Start the discussion